In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor ...
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In part three of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey ...
In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site ...
In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results